{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/AMLX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-17T03:57:13.898Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9690,"canonical_name":"Amylyx Pharmaceuticals, Inc.","cik":"0001658551","uei":null,"lei":null,"duns":null,"ticker":"AMLX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":39},"count":39,"timeline":[{"ts":"2026-10-05","kind":"sec.insider.30000","reporter":"MILNE GEORGE M JR","title":null,"shares":30000,"price_per_share":27.6968,"usd_value":830904,"security_title":"Common Stock","importance":15.830904},{"ts":"2026-09-14","kind":"sec.filing","form_type":"4","title":"4 — Amylyx Pharmaceuticals, Inc. — 2026-09-14","url_slug":"/sec/cik-0001658551/4/0001193125-26-390506","accession_number":"0001193125-26-390506","importance":30},{"ts":"2026-09-14","kind":"sec.filing","form_type":"4","title":"4 — Amylyx Pharmaceuticals, Inc. — 2026-09-14","url_slug":"/sec/cik-0001658551/4/0001193125-26-390507","accession_number":"0001193125-26-390507","importance":30},{"ts":"2026-09-14","kind":"sec.filing","form_type":"4","title":"4 — Amylyx Pharmaceuticals, Inc. — 2026-09-14","url_slug":"/sec/cik-0001658551/4/0001193125-26-390508","accession_number":"0001193125-26-390508","importance":30},{"ts":"2026-09-11","kind":"sec.form144","reporter":"Cohen Joshua B","title":"Officer, Director","shares":30464,"usd_value":980504,"security_title":"Common","approx_sale_date":"2026-09-10","accession_number":"0001193125-26-389243","importance":40.1961008},{"ts":"2026-09-11","kind":"sec.form144","reporter":"Klee Justin B.","title":"Officer, Director","shares":30464,"usd_value":980264,"security_title":"Common","approx_sale_date":"2026-09-10","accession_number":"0001193125-26-389247","importance":40.1960528},{"ts":"2026-09-11","kind":"sec.form144","reporter":"Frates James M","title":"Officer","shares":10810,"usd_value":349821,"security_title":"Common","approx_sale_date":"2026-09-10","accession_number":"0001193125-26-389246","importance":40.0699642},{"ts":"2026-09-11","kind":"sec.form144","reporter":"Bedrosian Camille L","title":"Officer","shares":10028,"usd_value":324868,"security_title":"Common","approx_sale_date":"2026-09-10","accession_number":"0001193125-26-389245","importance":40.0649736},{"ts":"2026-09-11","kind":"sec.form144","reporter":"Mazzariello Gina","title":"Officer","shares":9536,"usd_value":309506,"security_title":"Common","approx_sale_date":"2026-09-10","accession_number":"0001193125-26-389244","importance":40.0619012},{"ts":"2026-09-11","kind":"sec.filing","form_type":"144","title":"144 — Amylyx Pharmaceuticals, Inc. — 2026-09-11","url_slug":"/sec/cik-0001658551/144/0001193125-26-389247","accession_number":"0001193125-26-389247","importance":30},{"ts":"2026-09-11","kind":"sec.filing","form_type":"144","title":"144 — Amylyx Pharmaceuticals, Inc. — 2026-09-11","url_slug":"/sec/cik-0001658551/144/0001193125-26-389243","accession_number":"0001193125-26-389243","importance":30},{"ts":"2026-09-11","kind":"sec.filing","form_type":"144","title":"144 — Amylyx Pharmaceuticals, Inc. — 2026-09-11","url_slug":"/sec/cik-0001658551/144/0001193125-26-389244","accession_number":"0001193125-26-389244","importance":30},{"ts":"2026-09-10","kind":"sec.insider.29545","reporter":"Cohen Joshua B","title":"Co-Chief Executive Officer","shares":29545,"price_per_share":32.1557,"usd_value":950040,"security_title":"Common Stock","importance":15.9500401565},{"ts":"2026-09-10","kind":"sec.insider.29025","reporter":"Klee Justin B.","title":"Co-Chief Executive Officer","shares":29025,"price_per_share":32.1293,"usd_value":932553,"security_title":"Common Stock","importance":15.9325529325},{"ts":"2026-09-10","kind":"sec.insider.9768","reporter":"FRATES JAMES M","title":"Chief Financial Officer","shares":9768,"price_per_share":32.2681,"usd_value":315195,"security_title":"Common Stock","importance":15.3151948008},{"ts":"2026-09-10","kind":"sec.insider.9525","reporter":"Mazzariello Gina","title":"Chief Legal Officer","shares":9525,"price_per_share":32.4556,"usd_value":309140,"security_title":"Common Stock","importance":15.30913959},{"ts":"2026-09-10","kind":"sec.insider.7947","reporter":"Bedrosian Camille L","title":"Chief Medical Officer","shares":7947,"price_per_share":32.2139,"usd_value":256004,"security_title":"Common Stock","importance":15.2560038633},{"ts":"2026-09-10","kind":"sec.insider.2081","reporter":"Bedrosian Camille L","title":"Chief Medical Officer","shares":2081,"price_per_share":33.0919,"usd_value":68864,"security_title":"Common Stock","importance":15.0688642439},{"ts":"2026-09-10","kind":"sec.insider.1439","reporter":"Klee Justin B.","title":"Co-Chief Executive Officer","shares":1439,"price_per_share":33.1552,"usd_value":47710,"security_title":"Common Stock","importance":15.0477103328},{"ts":"2026-09-10","kind":"sec.insider.1042","reporter":"FRATES JAMES M","title":"Chief Financial Officer","shares":1042,"price_per_share":33.2302,"usd_value":34626,"security_title":"Common Stock","importance":15.0346258684},{"ts":"2026-09-10","kind":"sec.insider.919","reporter":"Cohen Joshua B","title":"Co-Chief Executive Officer","shares":919,"price_per_share":33.1488,"usd_value":30464,"security_title":"Common Stock","importance":15.0304637472},{"ts":"2026-09-10","kind":"sec.insider.11","reporter":"Mazzariello Gina","title":"Chief Legal Officer","shares":11,"price_per_share":33.34,"usd_value":367,"security_title":"Common Stock","importance":15.00036674},{"ts":"2026-09-08","kind":"sec.filing","form_type":"8-K","title":"8-K — Amylyx Pharmaceuticals, Inc. — 2026-09-08","url_slug":"/sec/cik-0001658551/8-k/0001193125-26-385331","accession_number":"0001193125-26-385331","importance":35},{"ts":"2026-09-02","kind":"sec.filing","form_type":"4","title":"4 — Amylyx Pharmaceuticals, Inc. — 2026-09-02","url_slug":"/sec/cik-0001658551/4/0001193125-26-380152","accession_number":"0001193125-26-380152","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"8-K","title":"8-K — Amylyx Pharmaceuticals, Inc. — 2026-08-20","url_slug":"/sec/cik-0001658551/8-k/0001193125-26-359418","accession_number":"0001193125-26-359418","importance":35},{"ts":"2026-08-20","kind":"sec.filing","form_type":"4","title":"4 — Amylyx Pharmaceuticals, Inc. — 2026-08-20","url_slug":"/sec/cik-0001658551/4/0001193125-26-359675","accession_number":"0001193125-26-359675","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"4","title":"4 — Amylyx Pharmaceuticals, Inc. — 2026-08-20","url_slug":"/sec/cik-0001658551/4/0001193125-26-359677","accession_number":"0001193125-26-359677","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"4","title":"4 — Amylyx Pharmaceuticals, Inc. — 2026-08-20","url_slug":"/sec/cik-0001658551/4/0001193125-26-359678","accession_number":"0001193125-26-359678","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"424B5","title":"424B5 — Amylyx Pharmaceuticals, Inc. — 2026-08-20","url_slug":"/sec/cik-0001658551/424b5/0001193125-26-359416","accession_number":"0001193125-26-359416","importance":30},{"ts":"2026-08-18","kind":"sec.filing","form_type":"8-K","title":"8-K — Amylyx Pharmaceuticals, Inc. — 2026-08-18","url_slug":"/sec/cik-0001658551/8-k/0001193125-26-354716","accession_number":"0001193125-26-354716","importance":35},{"ts":"2026-08-18","kind":"sec.filing","form_type":"8-K","title":"8-K — Amylyx Pharmaceuticals, Inc. — 2026-08-18","url_slug":"/sec/cik-0001658551/8-k/0001193125-26-354793","accession_number":"0001193125-26-354793","importance":35},{"ts":"2026-08-18","kind":"sec.filing","form_type":"424B5","title":"424B5 — Amylyx Pharmaceuticals, Inc. — 2026-08-18","url_slug":"/sec/cik-0001658551/424b5/0001193125-26-355696","accession_number":"0001193125-26-355696","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Amylyx Pharmaceuticals, Inc. — 2026-08-06","url_slug":"/sec/cik-0001658551/10-q/0001193125-26-336682","accession_number":"0001193125-26-336682","importance":45},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Amylyx Pharmaceuticals, Inc. — 2026-08-06","url_slug":"/sec/cik-0001658551/8-k/0001193125-26-336670","accession_number":"0001193125-26-336670","importance":35},{"ts":"2026-07-10","kind":"sec.insider.s","reporter":"Mazzariello Gina","title":"Chief Legal Officer","shares":15000,"price_per_share":17.6081,"usd_value":264122,"security_title":"Common Stock","importance":35.2641215},{"ts":"2026-07-09","kind":"sec.form144","reporter":"GINA MAZZARIELLO","title":"Officer","shares":30000,"usd_value":536400,"security_title":"Common","approx_sale_date":"2026-07-09","accession_number":"0001950047-26-006982","importance":40.10728},{"ts":"2026-07-09","kind":"sec.insider.s","reporter":"Mazzariello Gina","title":"Chief Legal Officer","shares":15000,"price_per_share":18.3164,"usd_value":274746,"security_title":"Common Stock","importance":35.274746},{"ts":"2026-07-09","kind":"sec.filing","form_type":"144","title":"144 — Amylyx Pharmaceuticals, Inc. — 2026-07-09","url_slug":"/sec/cik-0001658551/144/0001950047-26-006982","accession_number":"0001950047-26-006982","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Amylyx Pharmaceuticals, Inc. — 2026-06-04","url_slug":"/sec/cik-0001658551/8-k/0001193125-26-257390","accession_number":"0001193125-26-257390","importance":35}]}